GALLBLADDER CANCER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The global gallbladder cancer market size is projected to reach US$ 100.1 million by 2030, from US$ 73.5 million in 2023, at a CAGR of 4.5% during the forecast period. The increasing prevalence of gallbladder cancer is anticipated to increase the demand for treatment, subsequently driving the growth of the global gallbladder cancer treatment market. This combined with the rising adoption of minimally invasive surgical procedures and the growing focus on research and development of novel treatment options are expected to propel the market growth in the coming years.

Gallbladder Cancer Market Regional Insights

• North America is expected to be the largest market for gallbladder cancer during the forecast period, accounting for over 37% of the market share in 2023. The growth of the market in North America is attributed to the rising incidence of gallbladder cancer, presence of key players, and availability of advanced healthcare infrastructure in the region.
• The Europe market is expected to be the second-largest market for gallbladder cancer, accounting for over 28% of the market share in 2023. The growth of the market in Europe is attributed to the high healthcare expenditure and growing research on novel therapeutics in the region.
• The Asia Pacific market is expected to be the fastest-growing market for gallbladder cancer, with a CAGR of 6.2% over during the forecast period. The growth of the market in Asia Pacific is attributed to the large undiagnosed patient pool, improving healthcare infrastructure, and increasing awareness programs by governments and nongovernmental organization (NGO) in the region.

Figure 1. Global Gallbladder Cancer Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Analysts’ Views on the Global Gallbladder Cancer Market:

Gallbladder cancer is a serious condition with high mortality rates. It is more common in women and older adults. The market for gallbladder cancer includes various treatment modalities such as surgery, radiation therapy, and chemotherapy. The global gallbladder cancer market is expected to witness significant growth in the coming years. This growth is primarily driven by the increasing prevalence of gallbladder cancer worldwide, advancements in diagnostic technologies, and the development of novel therapeutics.

Gallbladder Cancer Market Drivers

• Increasing prevalence of gallbladder cancer: The rising incidence of gallbladder cancer globally is a major factor driving growth in the gallbladder cancer market. Gallbladder cancer is a relatively rare cancer, but rates have been slowly rising over the past few decades. For instance, according to data published by the Cancer Council Victoria in 2021, 288 Victorians were diagnosed with gallbladder cancer. Of these, there were 140 males and 148 females.
• Growing geriatric population: The gallbladder cancer market is also driven by the growing geriatric population across the globe. Gallbladder cancer usually affects older adults and incidence rates peak in the sixth and seventh decade of life. According to the United Nations, the global population aged 65 years or over is projected to grow from 727 million in 2020 to around 50 billion in 2050. The rapidly aging global population is therefore expected to drive the increasing demand for gallbladder cancer diagnostics and treatments.

Gallbladder Cancer Market Opportunities

• Huge unmet needs: There is lot of unmet need in the gallbladder cancer market. For instance, according to the data published by the American Society of Clinical Oncology (ASCO), it is estimated that 4,510 deaths (1,900 men and 2,610 female) from gallbladder and other biliary cancers will occur in the U.S. in 2023.

Gallbladder Cancer Market Trends

• Increasing research and development activities by the market players: Increasing research and development activities by the market players are expected to propel the market growth over the forecast period. For instance, on September 5, 2022, AstraZeneca, a pharmaceutical company, has received approval for Imfinzi (durvalumab) in the U.S. for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy.

Gallbladder Cancer Market Restraints

• High cost burden of cancer therapies: For example, according to statistics from the World Health Organization (WHO), gallbladder and biliary tract cancers are among the 10 most expensive cancers to treat in terms of initial workup and primary treatment costs. A surgery to remove the gallbladder (cholecystectomy) alone costs anywhere between US$ 20,000 to US$ 50,000 depending on the extent of surgery and hospitalization charges in different countries. Add to this the costs of pre-surgical tests like CT scans, MRIs, or biopsies which can cumulatively exceed US $10,000. Post-surgery, patients also require chemotherapy and radiation sessions. On an average, a single cycle of some of the commonly used chemotherapy drugs like gemcitabine costs US$ 3,000 to US$ 10,000. Radiation therapy sessions cost US$ 100 to US$ 500 per session and patients typically require 20 to 30 sessions. Prolonged hospital stays further add to the costs.
• Lack of approved targeted therapies: Despite research into molecular alterations in gallbladder cancer, limited targeted agents have received US FDA or European Medicines Agency (EMA) approval specifically for this indication. For instance, only one FGFR inhibitor pemigatinib has been approved so far despite the prevalence of FGFR fusions. Moreover, genomic testing to identify potential targets is also not widely adopted yet. Lack of regulatory approved targeted therapies tailored for advanced gallbladder cancer cases hinders market growth currently.

Recent Developments

• On October 21, 2023, Regeneron Pharmaceuticals, Inc., a pharmaceutical company, announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable Cutaneous Squamous Cell Carcinoma (CSCC)
• In June 2023, Sirnaomics Ltd., a biopharmaceutical company, announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma (isSCC) in situ into late-stage clinical development

Acquisition and partnerships

• On August 1, 2023, Replimune Group, Inc., a clinical stage biotechnology company, and Incyte, a global biopharmaceutical company, announced a clinical trial collaboration and supply agreement to study RP1, Replimune Group, Inc. lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor

Figure 2. Global Gallbladder Cancer Market Share (%), by Cancer Type, 2023

To learn more about this report, request sample copy

Top Companies in the Gallbladder Cancer Market

• Eli Lilly and Company
• Bristol-Myers Squibb
• Roche
• Pfizer
• Novartis
• Merck & Co., Inc.
• Sanofi
• AstraZeneca
• AbbVie
• Gilead Sciences

Definition: The gallbladder cancer market refers to the market and ecosystem centered around diagnosing and treating cancer that develops in the gallbladder. Gallbladder cancer is a relatively uncommon but a highly fatal disease. It most commonly takes the form of adenocarcinomas developing from the epithelial cells of the gallbladder. Diagnosis typically involves imaging tests like ultrasound, CT, MRI along with blood tests and biopsy. Treatment options include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies.

Few Other Promising Reports in Pharmaceuticals Industry

Lung cancer surgery market

Cancer Biopsy Market

Cancer Drugs Market

Pituitary Cancer Market